Biogen Aktie
WKN: 789617 / ISIN: US09062X1037
|
22.05.2024 14:11:37
|
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln
(RTTNews) - Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.
The proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences' expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases.
Biogen plans to leverage its existing global development and commercialization capabilities in rare disease and its strong scientific expertise in immunology to support the advancement of felzartamab and the HI-Bio pipeline.
The total potential deal value can go up to $1.8 billion, should the felzartamab programs achieve certain development milestones.
In addition to lead program felzartamab, the HI-Bio pipeline includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial.
Biogen seeks to retain expertise and talent from HI-Bio and establish a San Francisco Bay Area team focused on expanding our efforts in immune-mediated diseases.
Biogen expects to finance the acquisition with cash and may also draw on its revolving credit agreement. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals and is currently anticipated to close in the third quarter of 2024.
The acquisition of HI-Bio is not expected to impact Biogen's previously issued 2024 guidance.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
|
01.04.25 |
Dienstagshandel in New York: NASDAQ 100 klettert am Dienstagnachmittag (finanzen.at) | |
|
31.03.25 |
NASDAQ Composite Index-Titel Biogen-Aktie: So viel hätten Anleger mit einem Investment in Biogen von vor einem Jahr verloren (finanzen.at) | |
|
26.03.25 |
Börse New York: So entwickelt sich der NASDAQ 100 aktuell (finanzen.at) | |
|
24.03.25 |
NASDAQ Composite Index-Papier Biogen-Aktie: So viel Verlust hätte ein Biogen-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
|
19.03.25 |
NASDAQ-Handel: NASDAQ 100 beendet den Handel in der Gewinnzone (finanzen.at) | |
|
18.03.25 |
Schwache Performance in New York: NASDAQ 100 liegt im Minus (finanzen.at) | |
|
18.03.25 |
Verluste in New York: NASDAQ 100 zum Start leichter (finanzen.at) | |
|
17.03.25 |
NASDAQ Composite Index-Titel Biogen-Aktie: So viel Verlust hätte eine Biogen-Investition von vor 5 Jahren eingebracht (finanzen.at) |
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
| Biogen Inc | 121,60 | -1,50% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.